PRME
Prime Medicine, Inc.
A biotechnology company developing "Prime Editing," a gene-editing technology that acts like a molecular word processor, able to search for and rewrite faulty DNA without cutting both strands like earlier CRISPR "scissors." Founded in 2019, Prime Medicine aims to turn this science into one-time treatments for serious inherited diseases, and its lead therapy targets chronic granulomatous disease, a rare immune disorder. The company takes its name from the Prime Editing technology it was built around.
CUSIP: 74168J101HealthcareUS2 holders
Total Value
$48.27M
Total Shares
13.27M
Net Share Change
+2.04M
Activity
1 buying1 selling
Investor
Value
Shares
Weight
Change
